Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 6, 2026, 11:47 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 27 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Phentolamine Clear all
Completed Phase 3 Interventional Results available

Safety and Efficacy of Nyxol (0.75% Phentolamine Ophthalmic Solution) in Subjects With Dim Light Vision Disturbances

NCT04638660
View directory record Official record
Conditions
Dim Light Vision Disturbances
Interventions
Phentolamine Ophthalmic Solution 0.75%, Phentolamine Ophthalmic Solution Vehicle (Placebo)
Drug
Lead sponsor
Ocuphire Pharma, Inc.
Industry
Eligibility
18 Years and older
Enrollment
144 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
17
States / cities
Newport Beach, California • Petaluma, California • Jacksonville, Florida + 12 more
Source: ClinicalTrials.gov public record
Updated Oct 13, 2025 · Synced Sep 6, 2026, 11:47 AM EDT
Recruiting Early Phase 1 Interventional Accepts healthy volunteers

Sympathetic Vascular Transduction Across the Menopause Transition: Contributing Mechanisms

NCT06787066
View directory record Official record
Conditions
Menopause
Interventions
Propranolol Hydrochloride, Phentolamine Injection
Drug
Lead sponsor
University of Missouri-Columbia
Other
Eligibility
18 Years to 70 Years · Female only
Enrollment
75 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Columbia, Missouri
Source: ClinicalTrials.gov public record
Updated Sep 14, 2025 · Synced Sep 6, 2026, 11:47 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

The Safety and Efficacy of Phentolamine Mesylate Ophthalmic Solution in Subjects With Severe Night Vision Disturbances

NCT01703559
View directory record Official record
Conditions
Night Vision Complaints, Decrease in Night Vision, Disturbance; Vision, Loss
Interventions
Phentolamine Mesylate Ophthalmic Solution 1.0%, Phentolamine Mesylate Ophthalmic Solution 0.5%, Phentolamine Mesylate Ophthalmic Solution Vehicle (Placebo)
Drug · Other
Lead sponsor
Ocuphire Pharma, Inc.
Industry
Eligibility
18 Years to 45 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Jul 31, 2019 · Synced Sep 6, 2026, 11:47 AM EDT
Completed Phase 2 Interventional

Nerve-Sparing Radical Prostatectomy With or Without Nerve Grafting Followed by Standard Therapy for Erectile Dysfunction in Treating Patients With Localized Prostate Cancer

NCT00080808
View directory record Official record
Conditions
Prostate Cancer
Interventions
Alprostadil (E1), Papaverine, Phentolamine mesylate, Sildenafil citrate, conventional surgery
Drug · Procedure
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
Up to 65 Years · Male only
Enrollment
111 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2009
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 29, 2012 · Synced Sep 6, 2026, 11:47 AM EDT
Completed Phase 4 Interventional Results available

A Multiple Myeloma Trial in Patients With Bone Metastases

NCT00104104
View directory record Official record
Conditions
Multiple Myeloma
Interventions
zoledronic acid
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
179 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
68
States / cities
Huntsville, Alabama • Glendale, Arizona • Tucson, Arizona + 61 more
Source: ClinicalTrials.gov public record
Updated Jun 28, 2011 · Synced Sep 6, 2026, 11:47 AM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy of 0.75% Phentolamine Ophthalmic Solution in Subjects With Post-refractive Surgery Visual Disturbances

NCT06349759
View directory record Official record
Conditions
Mesopic Vision, Night Vision Loss
Interventions
phentolamine ophthalmic solution 0.75%, a non-selective alpha-1 and alpha-2 adrenergic antagonist, Placebo
Drug
Lead sponsor
Ocuphire Pharma, Inc.
Industry
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
25
States / cities
Pheonix, Arizona • Scottsdale, Arizona • Bakersfield, California + 20 more
Source: ClinicalTrials.gov public record
Updated Aug 17, 2026 · Synced Sep 6, 2026, 11:47 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Safety and Efficacy of Ophthalmic Phentolamine Mesylate to Reverse Pharmacologically Induced Mydriasis

NCT04024891
View directory record Official record
Conditions
Mydriasis, Dilation
Interventions
Phentolamine Mesylate Ophthalmic Solution 1%, Phentolamine Mesylate Ophthalmic Solution Vehicle (Placebo)
Drug · Other
Lead sponsor
Ocuphire Pharma, Inc.
Industry
Eligibility
18 Years to 45 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
4
States / cities
Pittsburg, Kansas • Lexington, Kentucky • Athens, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 28, 2023 · Synced Sep 6, 2026, 11:47 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Safety and Efficacy of Nyxol (0.75% Phentolamine Ophthalmic Solution) to Reverse Pharmacologically-Induced Mydriasis (MIRA-3)

NCT05134974
View directory record Official record
Conditions
Mydriasis, Dilation
Interventions
Phentolamine Ophthalmic Solution 0.75%, Phentolamine Ophthalmic Solution Vehicle
Drug
Lead sponsor
Ocuphire Pharma, Inc.
Industry
Eligibility
12 Years and older
Enrollment
368 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
15
States / cities
Newport Beach, California • Westminster, California • Delray Beach, Florida + 12 more
Source: ClinicalTrials.gov public record
Updated Aug 28, 2023 · Synced Sep 6, 2026, 11:47 AM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

: Vascular Function in Health and Disease

NCT02966665
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease, Pulmonary Artery Hypertension, Heart Failure, Hypertension
Interventions
Maximum Exercise Tests, BH4, L-NMMA, Vitamin C, Vitamin E, α-Lipoic Acid and L-Ascorbate, BQ-123, Fexofenadine, Ranitidine, Angiotensin-II, Valsartan, Acetylcholine, Sodium Nitroprusside, Angiotensin-II, Norepinephrine, Phentolamine, BQ-123, MitoQ, BH4
Other · Drug
Lead sponsor
Russell Richardson
Other
Eligibility
18 Years and older
Enrollment
420 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2026
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Sep 25, 2025 · Synced Sep 6, 2026, 11:47 AM EDT
Active, not recruiting Phase 3 Interventional

OPI-NXYDLD-303 Safety and Efficacy of Phentolamine Ophthalmic Solution in Keratorefractive Surgery Participants With Decreased Mesopic Visual Acuity

NCT07140783
View directory record Official record
Conditions
Vision Loss Night, Vision Disorders
Interventions
0.75% Phentolamine Ophthalmic Solution, Placebo
Drug
Lead sponsor
Ocuphire Pharma, Inc.
Industry
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
23
States / cities
Chandler, Arizona • Mesa, Arizona • Phoenix, Arizona + 18 more
Source: ClinicalTrials.gov public record
Updated Jun 21, 2026 · Synced Sep 6, 2026, 11:47 AM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy of Nyxol Eye Drops as a Single Agent and With Adjunctive Low-Dose Pilocarpine Eye Drops in Subjects With Presbyopia

NCT05646719
View directory record Official record
Conditions
Presbyopia
Interventions
Phentolamine Opthalmic Solution 0.75%, Placebo, Low dose pilocarpine, Low dose pilocarpine vehicle
Drug · Other
Lead sponsor
Ocuphire Pharma, Inc.
Industry
Eligibility
40 Years to 64 Years
Enrollment
333 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
26
States / cities
Phoenix, Arizona • Azusa, California • Newport Beach, California + 23 more
Source: ClinicalTrials.gov public record
Updated Jul 12, 2026 · Synced Sep 6, 2026, 11:47 AM EDT
Completed Phase 2 Interventional Results available

Single Dose Study of Phentolamine Mesylate Eye Drops in Patients With Severe Night Vision Disturbances

NCT04004507
View directory record Official record
Conditions
Decrease in Night Vision, Disturbance; Vision, Loss
Interventions
Phentolamine Mesylate Ophthalmic Solution 1%, Phentolamine Mesylate Ophthalmic Solution Vehicle (Placebo)
Drug · Other
Lead sponsor
Ocuphire Pharma, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
1
States / cities
Lynbrook, New York
Source: ClinicalTrials.gov public record
Updated Feb 14, 2024 · Synced Sep 6, 2026, 11:47 AM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy of Ophthalmic Phentolamine Mesylate in Glaucoma

NCT03960866
View directory record Official record
Conditions
Open Angle Glaucoma, Ocular Hypertension
Interventions
Phentolamine Mesylate Ophthalmic Solution 1%, Phentolamine Mesylate Ophthalmic Solution Vehicle (Placebo)
Drug · Other
Lead sponsor
Ocuphire Pharma, Inc.
Industry
Eligibility
18 Years and older
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
5
States / cities
Mission Hills, California • Morrow, Georgia • Ann Arbor, Michigan + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 12, 2023 · Synced Sep 6, 2026, 11:47 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Safety and Efficacy Study of NV-101 in Dental Patients

NCT00154167
View directory record Official record
Conditions
Soft Tissue Anesthesia (Numbness)
Interventions
NV-101 (phentolamine mesylate solution)
Drug
Lead sponsor
Novalar Pharmaceuticals, Inc.
Industry
Eligibility
10 Years to 65 Years
Enrollment
122 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003
U.S. locations
1
States / cities
Tacoma, Washington
Source: ClinicalTrials.gov public record
Updated Sep 13, 2005 · Synced Sep 6, 2026, 11:47 AM EDT
Completed Not applicable Interventional

Assessment of the Functional Significance of Accessory Pudendal Arteries

NCT00577876
View directory record Official record
Conditions
Prostate Cancer
Interventions
Trimix Injection with Doppler Ultrasound
Procedure
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older · Male only
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 26, 2011 · Synced Sep 6, 2026, 11:47 AM EDT
Completed Not applicable Interventional Results available

The Second Intensive Blood Pressure Reduction in Acute Cerebral Haemorrhage Trial

NCT00716079
View directory record Official record
Conditions
Intracerebral Hemorrhage, Stroke, Hypertension
Interventions
Blood pressure management policies
Other
Lead sponsor
The George Institute
Other
Eligibility
18 Years and older
Enrollment
2,839 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Dec 12, 2013 · Synced Sep 6, 2026, 11:47 AM EDT
Completed Early Phase 1 Interventional Results available

Adrenergic System in Islet Transplantation

NCT03079921
View directory record Official record
Conditions
Type1diabetes, Hypoglycemia, Hypoglycemia Unawareness, Islet Cell Transplantation
Interventions
Phentolamine, Propranolol, Placebo
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
21 Years to 65 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2025
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 26, 2026 · Synced Sep 6, 2026, 11:47 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Evaluate Efficacy and Safety of POS to Improve Distance-corrected Near Visual in Participants With Presbyopia

NCT06542497
View directory record Official record
Conditions
Presbyopia
Interventions
0.75% phentolamine ophthalmic solution, Placebo
Drug
Lead sponsor
Ocuphire Pharma, Inc.
Industry
Eligibility
45 Years to 64 Years
Enrollment
569 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2026
U.S. locations
39
States / cities
Chandler, Arizona • Mesa, Arizona • Phoenix, Arizona + 32 more
Source: ClinicalTrials.gov public record
Updated Aug 16, 2026 · Synced Sep 6, 2026, 11:47 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Safety and Efficacy of Nyxol (0.75% Phentolamine Ophthalmic Solution) to Reverse Pharmacologically-Induced Mydriasis

NCT04620213
View directory record Official record
Conditions
Mydriasis, Dilation
Interventions
Phentolamine Ophthalmic Solution 0.75%, Phentolamine Ophthalmic Solution Vehicle (Placebo)
Drug · Other
Lead sponsor
Ocuphire Pharma, Inc.
Industry
Eligibility
12 Years and older
Enrollment
185 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
12
States / cities
Newport Beach, California • San Diego, California • Longwood, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Sep 10, 2023 · Synced Sep 6, 2026, 11:47 AM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy of Nyxol With Pilocarpine Eye Drops in Subjects With Presbyopia

NCT04675151
View directory record Official record
Conditions
Presbyopia
Interventions
Phentolamine Ophthalmic Solution 0.75%, Pilocarpine, Placebo
Drug · Other
Lead sponsor
Ocuphire Pharma, Inc.
Industry
Eligibility
40 Years to 64 Years
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
17
States / cities
Laguna Hills, California • Newport Beach, California • Crystal River, Florida + 14 more
Source: ClinicalTrials.gov public record
Updated Oct 9, 2025 · Synced Sep 6, 2026, 11:47 AM EDT
Completed Phase 3 Interventional

Study of NV-101 for Efficacy, Pharmacodynamics, and Safety in Dental Patients Undergoing Maxillary Procedures

NCT00309335
View directory record Official record
Conditions
Anesthesia, Dental
Interventions
Phentolamine Mesylate (NV-101)
Drug
Lead sponsor
Novalar Pharmaceuticals, Inc.
Industry
Eligibility
12 Years and older
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 16, 2006 · Synced Sep 6, 2026, 11:47 AM EDT
Completed Phase 3 Interventional

Study of NV-101 for Efficacy, Pharmacodynamics, and Safety in Dental Patients Undergoing Mandibular Procedures

NCT00309361
View directory record Official record
Conditions
Anesthesia, Dental
Interventions
Phentolamine Mesylate (NV-101)
Drug
Lead sponsor
Novalar Pharmaceuticals, Inc.
Industry
Eligibility
12 Years and older
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 16, 2006 · Synced Sep 6, 2026, 11:47 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Nyxol (0.75% Phentolamine Ophthalmic Solution) to Reverse Pharmacologically-Induced Mydriasis in Pediatric Subjects

NCT05223478
View directory record Official record
Conditions
Mydriasis, Dilation
Interventions
Phentolamine Ophthalmic Solution 0.75%, Phentolamine Ophthalmic Solution Vehicle
Drug
Lead sponsor
Ocuphire Pharma, Inc.
Industry
Eligibility
3 Years to 11 Years
Enrollment
23 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
2
States / cities
Longwood, Florida • Athens, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 4, 2023 · Synced Sep 6, 2026, 11:47 AM EDT
Completed Phase 2 Interventional

Study of NV-101 for Safety and Efficacy in Pediatric Dental Patients Undergoing Procedures

NCT00309322
View directory record Official record
Conditions
Anesthesia, Dental
Interventions
Phentolamine Mesylate (NV-101)
Drug
Lead sponsor
Novalar Pharmaceuticals, Inc.
Industry
Eligibility
4 Years to 11 Years
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 16, 2006 · Synced Sep 6, 2026, 11:47 AM EDT